Please ensure Javascript is enabled for purposes of website accessibility

Alnylam Beats Revenue Estimates, but Misses on Earnings

By Taylor Carmichael – Feb 6, 2020 at 3:36PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares of the genetic disease specialist were essentially flat in late afternoon trading.

Alnylam Pharmaceuticals (ALNY -3.24%) reported its fourth-quarter and full 2019 financial results on Thursday, and its revenue growth was awesome -- up 240% year over year, which beat its estimates. But the large-cap biotech reported a worse loss than expected, missing its forecast by $0.25 a share. 

The company reported $71.7 million in sales for the fourth quarter, up from $21 million a year earlier. For the year, revenues were $219.8 million, up from $74.9 million in 2018. 

Y chromosome

Image source: Getty Images

Escalating revenues

Alnylam specializes in drugs based on RNA interference (RNAi), which can be used to suppress the action of malfunctioning genes that are causing genetic diseases. The company's lead compound, Onpattro, is approved to treat transthyretin-mediated amyloidosis (ATTR), a protein disorder that can cause organ damage. 

For the fourth quarter, Onpattro brought in $55.8 million for Alnylam. Overall, the drug had $166.4 million in sales in 2019. The biotech also reported collaborative revenues from Sanofi and Regeneron of $15.7 million for Q4, and $53.2 million for the full year.

In December, Alnylam was surprised with an early Food and Drug Administration approval for its second drug, Givlaari. It's the first approved treatment for acute hepatic porphyria, another genetic disorder. Givlaari has no significant revenues yet ($200,000). 

For 2020, Alnylam is forecasting that revenues will fall in the range of $285 million to $315 million for Onpattro. And the company believes that its collaboration revenues will jump to at least $100 million, and perhaps as high as $150 million. The company did not offer a 2020 sales forecast for the newly launched Givlaari.

Taylor Carmichael has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Alnylam Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alnylam Pharmaceuticals Stock Quote
Alnylam Pharmaceuticals
ALNY
$195.81 (-3.24%) $-6.56
Sanofi Stock Quote
Sanofi
SNY
$38.86 (-0.10%) $0.04
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$722.37 (-1.30%) $-9.49

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
338%
 
S&P 500 Returns
108%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.